Some believed this may be influenced by individual factors, including (1) mutation type as BRAFV600E mutant pLGGs may have different regrowth kinetics than fusion-BRAF tumors, (2) location of tumor within a vital area where risk of irreversible clinical damage can occur, and (3) whether the patient is on a clinical trial. Here, BRAF is linked to neoplasm.